Considering the common alterations in AKT signaling molecules found in breast cancers and as their use as targets of anticancer drugs [17,18], the AKT/mTOR pathway was further investigated to determine whether it was involved in the inhibition of breast cancer progression by COL17. Here, MTOR is linked to breast carcinoma.